All In Biotech

Drug Trial Radar · NCT04347239

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 484 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

484

Actual

Start

Apr 16, 2020

Primary completion

Oct 24, 2021

Study completion Jun 15, 2022

Sponsor

Lead sponsor
CytoDyn, Inc.Industry
Sponsor type
Industry
First posted
Apr 15, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.

Conditions

  • Coronavirus Disease 2019

Interventions

  • PlaceboDrug

    Placebo

  • Leronlimab (700mg)Drug

    Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause Mortality at Day 28Time frame: Mortality at day 28 (Visit 2, start of treatment = day 0)

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Advanced Cardiovascular, LLC

    Alexander City, Alabama

  • St. Jude Medical Center

    Fullerton, California

  • UCLA

    Los Angeles, California

  • James A. Haley Veterans' Hospital

    Tampa, Florida

  • Center for Advanced Research & Education (CARE)

    Gainesville, Georgia

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • St. Barnabas

    Livingston, New Jersey

  • Atlantic Health System Hospital

    Morristown, New Jersey

  • Holy Name Medical Center

    Teaneck, New Jersey

  • New York Community Hospital of Brooklyn

    Brooklyn, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Novant Health

    Winston-Salem, North Carolina

  • Ohio Health

    Columbus, Ohio

  • Good Samaritan Hospital Corvallis

    Corvallis, Oregon

  • Oregon Health and Sciences University

    Portland, Oregon

  • Baylor Scott & White Research Institute

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.